window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-15470191-1');

What’s in the News: Malaria Vaccine Shows Promise in Phase IIB Trial

Researchers with the University of Oxford recently reported promising findings from a trial of a candidate vaccine against malaria. The randomized, controlled, double-blind phase IIb trial included 450 children aged 5 to 17 months old in Burkina Faso in 2019. Split into three groups, the first two groups of participants received the R21/Matrix-M vaccine (with either a low or high dose of the Matrix-M adjuvant), and a third group received rabies vaccine as the control group. Efficacy was 77% in the high-dose adjuvant group and 71% in the low-dose adjuvant group over 12 months of follow-up, with no serious adverse events related to the vaccine. The vaccine is the first to reach the World Health Organization’s goal of a vaccine for malaria with at least 75% efficacy. The trial results were published as a preprint on April 20 and are in press at the Lancet, as recruitment for a phase III trial is underway, according to a University of Oxford news release. Malaria is estimated to cause more than 400,000 deaths globally each year, with the majority of these deaths in children.

if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = '';var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} var AdButler = AdButler || {}; = || []; var abkw = window.abkw || ''; var plc457187 = window.plc457187 || 0; document.write('');{handler: function(opt){ AdButler.register(165731, 457187, [728,90], 'placement_457187_', opt); }, opt: { place: plc457187++, keywords: abkw, domain: '', click:'CLICK_MACRO_PLACEHOLDER' }});

Improving the health of children worldwide through philanthropic support of scientific and educational programs.

This site uses cookies to provide a better experience for you